echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 77% of patients have T cell immune responses

    77% of patients have T cell immune responses

    • Last Update: 2021-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Brii Biosciences and VBI Vaccines announced today that the immunotherapy BRII-179 (VBI-2601) under investigation jointly developed by the two parties has been obtained in a phase 1b/2a clinical trial for the treatment of patients with chronic hepatitis B virus (HBV) infection Positive results


    The press release pointed out that the test data was announced at the European Association for the Study of the Liver (EASL) International Liver Conference (ILC) 2021 and has been selected as the "ILC Best" summary, which highlights the most noteworthy research in this year's scientific report


    Hepatitis B is one of the most important infectious disease threats in the world, with more than 290 million people infected worldwide


    VBI-2601 (BRII-179) is an innovative HBV immunotherapy based on recombinant protein.


    In this clinical trial, 49 non-cirrhotic patients with chronic hepatitis B were treated with nucleoside analogs (NUC) and received low-dose or high-dose VBI-2601 (BRII-179) treatment, with or without Interferon-α (IFN-α) treatment


    The main findings of the experiment include:

    All doses of BRII-179 (VBI-2601) combined with and without low-dose IFN-α therapy showed good tolerability, and no significant adverse events were found


    Note: The original text has been deleted

    Reference materials:

    [1] Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.